Price to Book Value (P/BV)
since 2005
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Price to Earnings (P/E) since 2005
- Price to Operating Profit (P/OP) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Danaher Corp., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Total Danaher stockholders’ equity1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Danaher Corp. Annual Report.
The price-to-book value (P/BV) ratio for the period examined exhibits considerable fluctuation, though generally trends upward over the long term. Initial values indicate a relatively high P/BV, followed by a period of decline, then a resurgence, and finally a recent moderation.
- Initial Period (2006-2009)
- From 2006 to 2009, the P/BV ratio decreased from 3.78 to 1.69. This decline coincided with a decrease in share price, particularly noticeable in 2008 and 2009, potentially reflecting broader economic conditions. While book value per share increased during this period, the share price decreased at a faster rate, driving down the ratio.
- Recovery and Growth (2010-2020)
- Between 2010 and 2020, the P/BV ratio generally increased, although not consistently. It rose from 2.07 in 2010 to 3.72 in 2020. This increase was driven by a more substantial increase in share price compared to the growth in book value per share. The period from 2016 to 2020 saw particularly strong growth in both share price and book value, resulting in a significant increase in the P/BV ratio.
- Recent Moderation (2021-2026)
- From 2021 to 2026, the P/BV ratio experienced a period of moderation and decline. The ratio peaked at 4.16 in 2021 before decreasing to 2.82 in 2026. While book value per share continued to increase, the share price experienced a more pronounced decrease, particularly in 2022 and 2024, leading to the observed decline in the P/BV ratio. The decrease in 2025 and 2026 suggests a potential shift in investor sentiment or market conditions.
- Overall Trend
- Despite the fluctuations, a long-term upward trend in the P/BV ratio is observable. The ratio started at 3.78 in 2006 and ended at 2.82 in 2026. This suggests that, over the period, the market has been willing to pay a higher price for each dollar of book value, potentially indicating increased confidence in the company’s ability to generate future earnings.
The P/BV ratio’s volatility suggests sensitivity to market conditions and company-specific factors. The periods of decline warrant further investigation to understand the underlying causes, while the overall upward trend indicates positive long-term market perception.
Comparison to Competitors
Danaher Corp., P/BV, long-term trends, comparison to competitors
| Danaher Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | ||||||||||||
| Feb 20, 2025 | ||||||||||||
| Feb 21, 2024 | ||||||||||||
| Feb 22, 2023 | ||||||||||||
| Feb 23, 2022 | ||||||||||||
| Feb 25, 2021 | ||||||||||||
| Feb 21, 2020 | ||||||||||||
| Feb 21, 2019 | ||||||||||||
| Feb 21, 2018 | ||||||||||||
| Feb 22, 2017 | ||||||||||||
| Feb 24, 2016 | ||||||||||||
| Feb 25, 2015 | ||||||||||||
| Feb 21, 2014 | ||||||||||||
| Feb 22, 2013 | ||||||||||||
| Feb 24, 2012 | ||||||||||||
| Feb 24, 2011 | ||||||||||||
| Feb 24, 2010 | ||||||||||||
| Feb 25, 2009 | ||||||||||||
| Feb 21, 2008 | ||||||||||||
| Mar 1, 2007 | ||||||||||||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Danaher Corp., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Danaher Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 24, 2026 | ||
| Feb 20, 2025 | ||
| Feb 21, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 25, 2021 | ||
| Feb 21, 2020 | ||
| Feb 21, 2019 | ||
| Feb 21, 2018 | ||
| Feb 22, 2017 | ||
| Feb 24, 2016 | ||
| Feb 25, 2015 | ||
| Feb 21, 2014 | ||
| Feb 22, 2013 | ||
| Feb 24, 2012 | ||
| Feb 24, 2011 | ||
| Feb 24, 2010 | ||
| Feb 25, 2009 | ||
| Feb 21, 2008 | ||
| Mar 1, 2007 | ||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Danaher Corp., P/BV, long-term trends, comparison to industry (health care)
| Danaher Corp. | Health Care | |
|---|---|---|
| Feb 24, 2026 | ||
| Feb 20, 2025 | ||
| Feb 21, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 25, 2021 | ||
| Feb 21, 2020 | ||
| Feb 21, 2019 | ||
| Feb 21, 2018 | ||
| Feb 22, 2017 | ||
| Feb 24, 2016 | ||
| Feb 25, 2015 | ||
| Feb 21, 2014 | ||
| Feb 22, 2013 | ||
| Feb 24, 2012 | ||
| Feb 24, 2011 | ||
| Feb 24, 2010 | ||
| Feb 25, 2009 | ||
| Feb 21, 2008 | ||
| Mar 1, 2007 | ||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).